Trial NCT04568031
Publication Asano M, Int J Infect Dis, 2021
Primary outcome on the report: 1) Immunogenicity, measured by anti-SARS-CoV-2 spike seroresponse (≥4-fold rise in titers from Day 1 baseline value) at Day 57; 2) Safety, measured by occurrence of solicited local and systemic reactogenicity signs/symptoms in the 6 days after each dose; occurrence of unsolicited AEs, serious AEs (SAEs), and AEs of special interest (AESIs) for 28 days after each dose; and change from baseline in safety laboratory measures

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.